Financial Contrast: Cue Biopharma (CUE) and Its Competitors

Share on StockTwits

Cue Biopharma (NASDAQ: CUE) is one of 570 public companies in the “Pharmaceutical preparations” industry, but how does it weigh in compared to its competitors? We will compare Cue Biopharma to related companies based on the strength of its dividends, earnings, valuation, profitability, risk, analyst recommendations and institutional ownership.

Valuation and Earnings

This table compares Cue Biopharma and its competitors top-line revenue, earnings per share (EPS) and valuation.

Gross Revenue Net Income Price/Earnings Ratio
Cue Biopharma $1.14 million -$38.98 million -4.14
Cue Biopharma Competitors $2.14 billion $227.41 million -116,312.19

Cue Biopharma’s competitors have higher revenue and earnings than Cue Biopharma. Cue Biopharma is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.

Analyst Recommendations

This is a summary of current ratings and target prices for Cue Biopharma and its competitors, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Cue Biopharma 0 0 1 0 3.00
Cue Biopharma Competitors 4951 13852 28890 1055 2.53

Cue Biopharma presently has a consensus target price of $14.50, suggesting a potential upside of 80.35%. As a group, “Pharmaceutical preparations” companies have a potential downside of 99.98%. Given Cue Biopharma’s stronger consensus rating and higher possible upside, equities analysts clearly believe Cue Biopharma is more favorable than its competitors.

Institutional and Insider Ownership

16.6% of Cue Biopharma shares are owned by institutional investors. Comparatively, 46.3% of shares of all “Pharmaceutical preparations” companies are owned by institutional investors. 16.8% of Cue Biopharma shares are owned by insiders. Comparatively, 15.7% of shares of all “Pharmaceutical preparations” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Profitability

This table compares Cue Biopharma and its competitors’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Cue Biopharma -3,233.51% -116.05% -90.83%
Cue Biopharma Competitors -1,458.54% -877.32% -28.68%

Risk & Volatility

Cue Biopharma has a beta of 1.23, suggesting that its share price is 23% more volatile than the S&P 500. Comparatively, Cue Biopharma’s competitors have a beta of 1.21, suggesting that their average share price is 21% more volatile than the S&P 500.

Summary

Cue Biopharma beats its competitors on 7 of the 13 factors compared.

Cue Biopharma Company Profile

Cue Biopharma, Inc., a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a protein biologic designed to target and activate antigen-specific T cells for human papilloma virus driven cancers. The company offers CUE-102, a non-viral antigen for cancers; CUE-103, an antigen; CUE-200 framework that includes CD80 and/or 4-1BBL to reactivate exhausted T cells and design to enhance antigen-specific T cell for the treatment of chronic infectious diseases; and CUE-300 framework to target various autoimmune diseases. It has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for Immuno-selective targeting and alteration of T cells (STAT) in the field of oncology; and Albert Einstein College of Medicine to develop Immuno-STAT biologics for chronic infectious diseases. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Receive News & Ratings for Cue Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cue Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

PM Capital Asian Opportunities Fund Ltd  to Issue $0.02 Final Dividend
PM Capital Asian Opportunities Fund Ltd to Issue $0.02 Final Dividend
2,911 Shares in Mitek Systems, Inc.  Purchased by Zurcher Kantonalbank Zurich Cantonalbank
2,911 Shares in Mitek Systems, Inc. Purchased by Zurcher Kantonalbank Zurich Cantonalbank
Zacks: Analysts Anticipate Prudential Financial Inc  to Announce $3.24 EPS
Zacks: Analysts Anticipate Prudential Financial Inc to Announce $3.24 EPS
Johnson & Johnson  Shares Bought by Westpac Banking Corp
Johnson & Johnson Shares Bought by Westpac Banking Corp
Canadian Imperial Bank of Commerce  PT Lowered to C$124.00 at Royal Bank of Canada
Canadian Imperial Bank of Commerce PT Lowered to C$124.00 at Royal Bank of Canada
X-trackers MSCI Europe Hedged Equity Fund  Stock Price Down 0.9%
X-trackers MSCI Europe Hedged Equity Fund Stock Price Down 0.9%


 
© 2006-2019 Zolmax.